215 related articles for article (PubMed ID: 18072266)
1. Stereochemical comparison of nebivolol with other beta-blockers.
Siebert CD; Hänsicke A; Nagel T
Chirality; 2008 Feb; 20(2):103-9. PubMed ID: 18072266
[TBL] [Abstract][Full Text] [Related]
2. Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol.
Ignarro LJ
Cardiovasc Ther; 2008; 26(2):115-34. PubMed ID: 18485134
[TBL] [Abstract][Full Text] [Related]
3. The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various beta-adrenergic blockers.
Pauwels PJ; Gommeren W; Van Lommen G; Janssen PA; Leysen JE
Mol Pharmacol; 1988 Dec; 34(6):843-51. PubMed ID: 2462161
[TBL] [Abstract][Full Text] [Related]
4. Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1-blocker.
Prisant LM
J Clin Pharmacol; 2008 Feb; 48(2):225-39. PubMed ID: 18083889
[TBL] [Abstract][Full Text] [Related]
5. Beta-blockers in the management of hypertension: focus on nebivolol.
Wojciechowski D; Papademetriou V
Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):471-9. PubMed ID: 18402537
[TBL] [Abstract][Full Text] [Related]
6. Molecular dynamics simulations reveal fundamental role of water as factor determining affinity of binding of beta-blocker nebivolol to beta(2)-adrenergic receptor.
Kaszuba K; Róg T; Bryl K; Vattulainen I; Karttunen M
J Phys Chem B; 2010 Jul; 114(25):8374-86. PubMed ID: 20524635
[TBL] [Abstract][Full Text] [Related]
7. Nebivolol: a third-generation beta-adrenergic blocker.
Veverka A; Nuzum DS; Jolly JL
Ann Pharmacother; 2006; 40(7-8):1353-60. PubMed ID: 16822893
[TBL] [Abstract][Full Text] [Related]
8. [Role of the L-arginine/nitric oxide system in the action of nebivolol].
Brodde OE; Philipp T
Dtsch Med Wochenschr; 2006 Nov; 131(45):2545-50. PubMed ID: 17091442
[TBL] [Abstract][Full Text] [Related]
9. Beta-adrenoceptor-mediated cAMP accumulation in cardiac cells: effects of nebivolol.
Pauwels PJ; Leysen JE; Janssen PA
Eur J Pharmacol; 1989 Dec; 172(6):471-9. PubMed ID: 2575531
[TBL] [Abstract][Full Text] [Related]
10. Evolving mechanisms of action of beta blockers: focus on nebivolol.
Mason RP; Giles TD; Sowers JR
J Cardiovasc Pharmacol; 2009 Aug; 54(2):123-8. PubMed ID: 19528811
[TBL] [Abstract][Full Text] [Related]
11. Effect of DL-nebivolol, its enantiomers and metabolites on the intracellular production of superoxide and nitric oxide in human endothelial cells.
Evangelista S; Garbin U; Pasini AF; Stranieri C; Boccioletti V; Cominacini L
Pharmacol Res; 2007 Apr; 55(4):303-9. PubMed ID: 17280840
[TBL] [Abstract][Full Text] [Related]
12. Nebivolol: the somewhat-different beta-adrenergic receptor blocker.
Münzel T; Gori T
J Am Coll Cardiol; 2009 Oct; 54(16):1491-9. PubMed ID: 19815121
[TBL] [Abstract][Full Text] [Related]
13. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide.
Gupta S; Wright HM
Cardiovasc Ther; 2008; 26(3):189-202. PubMed ID: 18786089
[TBL] [Abstract][Full Text] [Related]
14. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol.
Dessy C; Saliez J; Ghisdal P; Daneau G; Lobysheva II; Frérart F; Belge C; Jnaoui K; Noirhomme P; Feron O; Balligand JL
Circulation; 2005 Aug; 112(8):1198-205. PubMed ID: 16116070
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of nebivolol.
Janssens WJ
J Pharm Belg; 1992; 47(4):323-7. PubMed ID: 1357130
[TBL] [Abstract][Full Text] [Related]
16. No-dependent vasodilation induced by nebivolol in coronary circulation is not mediated by beta-adrenoceptors or by 5 HT1A-receptors.
Chlopicki S; Kozlovski VI; Gryglewski RJ
J Physiol Pharmacol; 2002 Dec; 53(4 Pt 1):615-24. PubMed ID: 12512696
[TBL] [Abstract][Full Text] [Related]
17. ENOS is not activated by nebivolol in human failing myocardium.
Brixius K; Song Q; Malick A; Boelck B; Addicks K; Bloch W; Mehlhorn U; Schwinger RH
Life Sci; 2006 Aug; 79(13):1234-41. PubMed ID: 16716362
[TBL] [Abstract][Full Text] [Related]
18. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker.
Ignarro LJ
Blood Press Suppl; 2004 Oct; 1():2-16. PubMed ID: 15587107
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and pharmacological properties of nebivolol, a new antihypertensive compound.
Van Lommen G; De Bruyn M; Schroven M
J Pharm Belg; 1990; 45(6):355-60. PubMed ID: 1982295
[TBL] [Abstract][Full Text] [Related]
20. Nitric oxide mechanisms of nebivolol.
Maffei A; Lembo G
Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):317-27. PubMed ID: 19443516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
